Biohaven Reports Third Quarter 2024 Financial Results and Recent Business Developments
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/4/2026
- S&P 500, Dow slide after jobs report fuels rate-hike bets
- US nonfarm payrolls surge in August; unemployment rate steady at 4.1%
- BofA's Hartnett says stay long commodities and gold as 'policy panic' works
- Oil slides on Friday, heads for weekly gain on US-Iran fight
- TikTok owner ByteDance said to secure $29.6bn loan for AI push
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Biohaven Pharmaceutical Holding (BHVN) PT Lowered to $66 at RBC Capital
November 13, 2024 6:44 AM ESTRBC Capital analyst Leonid Timashev lowered the price target on Biohaven Pharmaceutical Holding (NYSE: BHVN) to $66.00 (from $68.00) while maintaining a Outperform rating.
The analyst comments "This afternoon BHVN reported 3Q24 earnings. The company's pipeline remains on track for key value... More
